BidaskClub downgraded shares of EXACT Sciences (NASDAQ:EXAS) from a strong-buy rating to a buy rating in a report released on Wednesday morning.

A number of other equities analysts have also commented on the stock. Bank of America set a $56.00 price objective on shares of EXACT Sciences and gave the stock a buy rating in a research note on Thursday, October 19th. Canaccord Genuity reiterated a buy rating and issued a $45.00 target price on shares of EXACT Sciences in a research report on Thursday, September 7th. Leerink Swann reiterated an outperform rating and issued a $67.00 target price (up previously from $63.00) on shares of EXACT Sciences in a research report on Monday, November 13th. Robert W. Baird downgraded shares of EXACT Sciences from an outperform rating to a neutral rating and set a $56.00 target price for the company. in a research report on Monday, November 13th. Finally, Jefferies Group increased their target price on shares of EXACT Sciences to $60.00 and gave the stock a buy rating in a research report on Tuesday, October 31st. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $50.58.

EXACT Sciences (EXAS) traded down $0.61 during trading on Wednesday, reaching $53.83. 1,532,605 shares of the company were exchanged, compared to its average volume of 1,238,164. EXACT Sciences has a 1 year low of $13.05 and a 1 year high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The firm had revenue of $72.60 million during the quarter, compared to analyst estimates of $65.03 million. During the same quarter last year, the business posted ($0.36) EPS. The company’s revenue was up 158.4% on a year-over-year basis. equities analysts forecast that EXACT Sciences will post -1.12 EPS for the current year.

In other news, insider Graham Peter Lidgard sold 45,770 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $58.27, for a total transaction of $2,667,017.90. Following the transaction, the insider now owns 237,820 shares in the company, valued at approximately $13,857,771.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin T. Conroy sold 121,849 shares of the firm’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $53.45, for a total transaction of $6,512,829.05. Following the transaction, the insider now owns 951,901 shares in the company, valued at approximately $50,879,108.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 595,396 shares of company stock valued at $32,953,769. Insiders own 4.00% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in EXAS. Fred Alger Management Inc. bought a new position in shares of EXACT Sciences during the 2nd quarter valued at $84,177,000. Lord Abbett & CO. LLC raised its holdings in shares of EXACT Sciences by 59.1% during the 2nd quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after purchasing an additional 875,527 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of EXACT Sciences during the 2nd quarter valued at $29,450,000. Vanguard Group Inc. raised its holdings in shares of EXACT Sciences by 8.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after purchasing an additional 700,051 shares in the last quarter. Finally, Green Valley Investors LLC bought a new position in shares of EXACT Sciences during the 2nd quarter valued at $20,892,000. Institutional investors and hedge funds own 82.39% of the company’s stock.

WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/09/exact-sciences-exas-cut-to-buy-at-bidaskclub.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Stock Ratings for EXACT Sciences Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co. and related stocks with our FREE daily email newsletter.